Real-time Estimate
Cboe BZX
11:24:59 2024-06-04 am EDT
|
5-day change
|
1st Jan Change
|
17.17
USD
|
-1.38%
|
|
-0.17%
|
+56.58%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
753.2
|
565.1
|
694.3
|
1,626
|
-
|
-
|
Enterprise Value (EV)
1 |
472.4
|
213.2
|
375.9
|
1,464
|
1,442
|
1,626
|
P/E ratio
|
-13.4
x
|
-7.1
x
|
-6.97
x
|
-10.9
x
|
-8.8
x
|
-10.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
141
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
141
x
|
EV / EBITDA
|
-11
x
|
-2.99
x
|
-3.33
x
|
-10.3
x
|
-8.43
x
|
-7.86
x
|
EV / FCF
|
-13.8
x
|
-3.66
x
|
-3.85
x
|
-17
x
|
-13.5
x
|
-
|
FCF Yield
|
-7.23%
|
-27.3%
|
-26%
|
-5.87%
|
-7.42%
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
49,296
|
63,214
|
63,462
|
93,399
|
-
|
-
|
Reference price
2 |
15.28
|
8.940
|
10.94
|
17.41
|
17.41
|
17.41
|
Announcement Date
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
11.5
|
EBITDA
1 |
-
|
-42.94
|
-71.29
|
-112.8
|
-141.6
|
-171.1
|
-206.8
|
EBIT
1 |
-
|
-43.22
|
-71.66
|
-114.4
|
-146.4
|
-191.3
|
-217.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,890.31%
|
Earnings before Tax (EBT)
1 |
-
|
-42.81
|
-67.64
|
-100.2
|
-129.3
|
-171
|
-197.9
|
Net income
1 |
-17.12
|
-42.81
|
-67.64
|
-100.2
|
-132
|
-178
|
-183.9
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,599.14%
|
EPS
2 |
-0.1224
|
-1.140
|
-1.260
|
-1.570
|
-1.594
|
-1.979
|
-1.715
|
Free Cash Flow
1 |
-
|
-34.18
|
-58.18
|
-97.69
|
-86
|
-107
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-12.74
|
-14.74
|
-16.39
|
-18.16
|
-21.99
|
-25.51
|
-
|
-29
|
-33.38
|
-34.28
|
-34.7
|
-35.23
|
-36.15
|
-
|
-
|
EBIT
1 |
-12.82
|
-14.83
|
-16.49
|
-18.26
|
-22.08
|
-25.7
|
-25.34
|
-29.45
|
-33.86
|
-34.75
|
-35.65
|
-36.95
|
-38.96
|
-40.73
|
-43.82
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-12.7
|
-14.66
|
-16.07
|
-17.5
|
-19.42
|
-22.84
|
-21.47
|
-25.71
|
-30.14
|
-28.52
|
-31.96
|
-33.48
|
-34.62
|
-40.73
|
-43.82
|
Net income
1 |
-12.7
|
-14.66
|
-16.07
|
-17.5
|
-19.42
|
-22.84
|
-21.47
|
-25.71
|
-30.14
|
-28.52
|
-32.81
|
-34.38
|
-35.68
|
-40.73
|
-43.82
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2600
|
-0.3000
|
-0.3200
|
-0.3400
|
-0.3100
|
-0.3600
|
-0.3400
|
-0.4100
|
-0.4700
|
-0.3300
|
-0.3565
|
-0.3698
|
-0.3852
|
-0.3800
|
-0.4200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/11/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/11/23
|
8/10/23
|
11/9/23
|
2/22/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
281
|
352
|
318
|
162
|
184
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-34.2
|
-58.2
|
-97.7
|
-86
|
-107
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-21.3%
|
-21.8%
|
-30.1%
|
-30.2%
|
-32.3%
|
-26.5%
|
ROA (Net income/ Total Assets)
|
-
|
-20.6%
|
-20.7%
|
-28.3%
|
-28.2%
|
-29.9%
|
-24.9%
|
Assets
1 |
-
|
208.2
|
326.2
|
353.6
|
467.4
|
595.8
|
737.9
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
5.55
|
5.75
|
2
|
2
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
17.41
USD Average target price
32.5
USD Spread / Average Target +86.67% Consensus |
1st Jan change
|
Capi.
|
---|
| +56.58% | 1.63B | | +44.41% | 56.65B | | -6.87% | 39.44B | | +39.41% | 39.03B | | -11.17% | 26.86B | | +12.71% | 26.75B | | -21.94% | 19.03B | | +1.42% | 12.28B | | +24.44% | 12.26B | | +27.42% | 12.04B |
Other Biotechnology & Medical Research
|